Predictive analytics company OWKIN today announced an $11 million Series A funding round, led by Otium Venture, with participation from Cathay Innovation, Plug and Play, and NJF Capital.
OWKIN’s flagship platform, OWKIN Socrates, is intended for pharmaceutical researchers at the preclinical and clinical trial phases, and it is also used by hospital physician-researchers. OWKIN Socrates uses machine learning-based modeling to analyze molecular and imaging libraries as well as patient datasets, with the goal of uncovering complex biomarker patterns that cause disease. Unlike other platforms, OWKIN Socrates uses transfer learning, a type of artificial intelligence that focuses on the ability of a machine algorithm to improve learning capacities on a given dataset through previous exposure to a different one.
OWKIN will use the funds to scale its iplatform, cultivate high-value partnerships with leading healthcare organizations, and fuel internal growth.